- Home
- MCW vs IBRX Comparison
MCW vs IBRX Comparison
Compare MCW & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCW
- IBRX
- Stock Information
- Founded
- MCW 1996
- IBRX 2014
- Country
- MCW United States
- IBRX United States
- Employees
- MCW N/A
- IBRX N/A
- Industry
- MCW
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCW
- IBRX Health Care
- Exchange
- MCW Nasdaq
- IBRX Nasdaq
- Market Cap
- MCW 2.4B
- IBRX 2.4B
- IPO Year
- MCW 2021
- IBRX N/A
- Fundamental
- Price
- MCW $7.05
- IBRX $2.47
- Analyst Decision
- MCW Hold
- IBRX Strong Buy
- Analyst Count
- MCW 6
- IBRX 5
- Target Price
- MCW $8.50
- IBRX $11.35
- AVG Volume (30 Days)
- MCW 1.8M
- IBRX 8.0M
- Earning Date
- MCW 04-30-2025
- IBRX 05-08-2025
- Dividend Yield
- MCW N/A
- IBRX N/A
- EPS Growth
- MCW N/A
- IBRX N/A
- EPS
- MCW 0.21
- IBRX N/A
- Revenue
- MCW $994,727,000.00
- IBRX $14,745,000.00
- Revenue This Year
- MCW $7.47
- IBRX $621.53
- Revenue Next Year
- MCW $7.76
- IBRX $163.57
- P/E Ratio
- MCW $33.57
- IBRX N/A
- Revenue Growth
- MCW 7.30
- IBRX 2270.58
- 52 Week Low
- MCW $5.84
- IBRX $2.28
- 52 Week High
- MCW $8.60
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- MCW 38.51
- IBRX 41.67
- Support Level
- MCW $6.99
- IBRX $2.35
- Resistance Level
- MCW $7.34
- IBRX $3.04
- Average True Range (ATR)
- MCW 0.37
- IBRX 0.28
- MACD
- MCW -0.06
- IBRX -0.02
- Stochastic Oscillator
- MCW 22.40
- IBRX 13.19
About MCW Mister Car Wash Inc.
Mister Car Wash Inc is a car wash brand offering express exterior and interior cleaning services. Express Exterior Locations offers express exterior cleaning services and Interior Cleaning Locations offers both express exterior and interior cleaning services. The company recognizes revenue from activities related to providing car wash services at its car wash locations that are geographically diversified throughout the United States and have similar economic characteristics and nature of services.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.